Double Digit NASDAQ Stock Winners: MRM, RNAZ, TCRX
9:08 am Friday, September 24th, 2021
Following are major stock gainers on Nasdaq in Thursday’s trading session:
MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) was the active stock gainer on Thursday and soared 73% to $12.80. MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in two segments, Relaxation Salon and Digital Preventative Healthcare. The Relaxation Salon segment own, develops, operates, franchises, and supports relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) stock surged 53% to $4.02 after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. The preclinical study developed a radio-labeled derivative of TTX-MC138 tagged with Cu-64 for highly sensitive and specific quantitative determination of its pharmacokinetics, biodistribution, and observation, delivered to metastases via noninvasive positron emission tomography-magnetic resonance imaging (PET-MRI).
The results demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions, thus suggesting that the TTX platform delivers its therapeutic candidate as intended.
TScan Therapeutics, Inc. (NASDAQ:TCRX) moved up 25% to $7.69. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
